136 related articles for article (PubMed ID: 18308654)
1. Expression of cytokeratin 19 in the diagnosis of thyroid papillary carcinoma by quantitative polymerase chain reaction.
Flanagan JN; Pineda P; Knapp PE; De Las Morenas A; Lee SL; Braverman LE
Endocr Pract; 2008 Mar; 14(2):168-74. PubMed ID: 18308654
[TBL] [Abstract][Full Text] [Related]
2. [Detection of cytokeratin 19 and thyroperoxidase expressions in the diagnosis of thyroid diseases].
Yang QX; Shao CK; Feng ZY; Huang BQ; Han AJ; Xiong M; Zhao WL; Wu TT
Di Yi Jun Yi Da Xue Xue Bao; 2005 Jun; 25(6):678-81. PubMed ID: 15958307
[TBL] [Abstract][Full Text] [Related]
3. Fine-needle aspiration biopsy of papillary thyroid carcinoma: diagnostic utility of cytokeratin 19 immunostaining.
Nasser SM; Pitman MB; Pilch BZ; Faquin WC
Cancer; 2000 Oct; 90(5):307-11. PubMed ID: 11038428
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic utility of CK19 and CD56 in the differentiation of thyroid papillary carcinoma from its mimics.
Abouhashem NS; Talaat SM
Pathol Res Pract; 2017 May; 213(5):509-517. PubMed ID: 28214214
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical diagnosis of papillary thyroid carcinoma.
Cheung CC; Ezzat S; Freeman JL; Rosen IB; Asa SL
Mod Pathol; 2001 Apr; 14(4):338-42. PubMed ID: 11301350
[TBL] [Abstract][Full Text] [Related]
6. [Usefulness of CK19, HBME-1 and galectin-3 expressions in differential diagnosis of thyroid papillary microcarcinoma from benign lesions].
Tong J; Wang Y; Da JP
Zhonghua Zhong Liu Za Zhi; 2011 Aug; 33(8):599-604. PubMed ID: 22325220
[TBL] [Abstract][Full Text] [Related]
7. DNA repair proteins may differentiate papillary thyroid cancer from chronic lymphocytic thyroiditis and nodular colloidal goiter.
Evren B; Yılmaz S; Karadağ N; Sertkaya AÇ; Topaloğlu Ö; Kılınç F
Sci Rep; 2021 May; 11(1):9932. PubMed ID: 33976347
[TBL] [Abstract][Full Text] [Related]
8. HBME-1 and CK19 are highly discriminatory in the cytological diagnosis of papillary thyroid carcinoma.
Nga ME; Lim GS; Soh CH; Kumarasinghe MP
Diagn Cytopathol; 2008 Aug; 36(8):550-6. PubMed ID: 18618720
[TBL] [Abstract][Full Text] [Related]
9. Clinicopathological characterization and prognostic implication of FOXP3 and CK19 expression in papillary thyroid carcinoma and concomitant Hashimoto's thyroiditis.
Mohamed SY; Ibrahim TR; Elbasateeny SS; Abdelaziz LA; Farouk S; Yassin MA; Embaby A
Sci Rep; 2020 Jun; 10(1):10651. PubMed ID: 32606302
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic significance of CK19, TG, Ki67 and galectin-3 expression for papillary thyroid carcinoma in the northeastern region of China.
Song Q; Wang D; Lou Y; Li C; Fang C; He X; Li J
Diagn Pathol; 2011 Dec; 6():126. PubMed ID: 22188859
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic utility of cytokeratin 19 expression in multinodular goiter with papillary areas and papillary carcinoma of thyroid.
Erkiliç S; Aydin A; Koçer NE
Endocr Pathol; 2002; 13(3):207-11. PubMed ID: 12446919
[TBL] [Abstract][Full Text] [Related]
12. Interpretation of RET immunostaining in follicular lesions of the thyroid.
Cerilli LA; Mills SE; Rumpel CA; Dudley TH; Moskaluk CA
Am J Clin Pathol; 2002 Aug; 118(2):186-93. PubMed ID: 12162676
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic value of CD56 immunohistochemistry in thyroid lesions.
Pyo JS; Kim DH; Yang J
Int J Biol Markers; 2018 May; 33(2):161-167. PubMed ID: 29799356
[TBL] [Abstract][Full Text] [Related]
14. Expression of papillary thyroid carcinoma-associated molecular markers and their significance in follicular epithelial dysplasia with papillary thyroid carcinoma-like nuclear alterations in Hashimoto's thyroiditis.
Ma H; Yan J; Zhang C; Qin S; Qin L; Liu L; Wang X; Li N
Int J Clin Exp Pathol; 2014; 7(11):7999-8007. PubMed ID: 25550843
[TBL] [Abstract][Full Text] [Related]
15. A germline mutation (A339V) in thyroid transcription factor-1 (TITF-1/NKX2.1) in patients with multinodular goiter and papillary thyroid carcinoma.
Ngan ES; Lang BH; Liu T; Shum CK; So MT; Lau DK; Leon TY; Cherny SS; Tsai SY; Lo CY; Khoo US; Tam PK; Garcia-Barceló MM
J Natl Cancer Inst; 2009 Feb; 101(3):162-75. PubMed ID: 19176457
[TBL] [Abstract][Full Text] [Related]
16. Absence of the BRAF mutation in HBME1+ and CK19+ atypical cell clusters in Hashimoto thyroiditis: supportive evidence against preneoplastic change.
Nasr MR; Mukhopadhyay S; Zhang S; Katzenstein AL
Am J Clin Pathol; 2009 Dec; 132(6):906-12. PubMed ID: 19926583
[TBL] [Abstract][Full Text] [Related]
17. Galectin-1 is a diagnostic marker involved in thyroid cancer progression.
Arcolia V; Journe F; Wattier A; Leteurtre E; Renaud F; Gabius HJ; Remmelink M; Decaestecker C; Rodriguez A; Boutry S; Laurent S; Saussez S
Int J Oncol; 2017 Sep; 51(3):760-770. PubMed ID: 28677745
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic significance of CK19, RET, galectin-3 and HBME-1 expression for papillary thyroid carcinoma.
Zhu X; Sun T; Lu H; Zhou X; Lu Y; Cai X; Zhu X
J Clin Pathol; 2010 Sep; 63(9):786-9. PubMed ID: 20644217
[TBL] [Abstract][Full Text] [Related]
19. Cytokeratin subtypes in thyroid tumours: immunohistochemical study with emphasis on the follicular variant of papillary carcinoma.
Cameron BR; Berean KW
J Otolaryngol; 2003 Oct; 32(5):319-22. PubMed ID: 14974863
[TBL] [Abstract][Full Text] [Related]
20. Cytokeratin 19 immunolocalization in cell block preparation of thyroid aspirates. An adjunct to fine-needle aspiration diagnosis of papillary thyroid carcinoma.
Khurana KK; Truong LD; LiVolsi VA; Baloch ZW
Arch Pathol Lab Med; 2003 May; 127(5):579-83. PubMed ID: 12708901
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
